tert-butyl 4-((4-chlorophenyl)carbamoyl)piperazine-1-carboxylate | 1315592-03-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-((4-chlorophenyl)carbamoyl)piperazine-1-carboxylate
• 英文别名: 1-Piperazinecarboxylic acid, 4-[[(4-chlorophenyl)amino]carbonyl]-, 1,1-dimethylethyl ester；tert-butyl 4-[(4-chlorophenyl)carbamoyl]piperazine-1-carboxylate
• CAS: 1315592-03-0
• 化学式: C₁₆H₂₂ClN₃O₃
• 分子量: 339.822
• InChiKey: XWDPRPYPBGEBBH-UHFFFAOYSA-N

物化性质

• 沸点：
  507.7±50.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((4-chlorophenyl)carbamoyl)piperazine-1-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N¹-(4-chlorophenyl)-N⁴-((S)-4-(neopentylamino)-1,4-dioxo-1-(((S)-1-oxo-4-phenyl-1-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)amino)butan-2-yl)amino)butan-2-yl)piperazine-1,4-dicarboxamide
  参考文献：
  名称：

  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114211
• 作为产物：
  描述：

  对氯苯胺 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 tert-butyl 4-((4-chlorophenyl)carbamoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  苯喹啉瞬态受体潜在的香草酸1拮抗剂治疗疼痛：1-（2-苯基喹啉-4-羰基）-N-（4-（三氟甲基）苯基）吡咯烷-3-羧酰胺的发现

  摘要：

  本文报道的是设计，合成和药理学表征的一类在从喹古芬铅进化而来的苯基喹啉平台上构建的TRPV1拮抗剂。该设计包括三个部分：连接到脂族羧酰胺的苯基喹啉头基，该端基被束缚在苯基尾基上。该设计的优化导致鉴定出37个，其中包括一个吡咯烷连接子和一个三氟甲基-苯基尾巴。在TRPV1功能测定中，使用表达hTRPV1的细胞，有37种拮抗辣椒素诱导的Ca 2+内流，IC 50值为10.2 nM。在完整的小鼠镇痛模型中，37在不同的疼痛模型中，与阳性对照BCTC相比，它们显示出更好的抗伤害感受活性。所有这些结果表明，可以考虑将37种药物作为抗伤害性药物进一步开发的主要候选药物。

  DOI：

  10.1016/j.bmc.2017.12.048

文献信息

• TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF
  申请人：ZHEJIANG UNIVERSITY

  公开号：US20170022250A1

  公开（公告）日：2017-01-26

  Disclosed are a tripeptide epoxyketone compound, a preparation method thereof, and a use thereof in the preparation of anti-tumor drugs.

  公开了一种三肽环氧酮化合物，其制备方法及其在抗肿瘤药物制备中的用途。
• 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：US10717716B2

  公开（公告）日：2020-07-21

  The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

  本发明涉及具有组蛋白去乙酰化酶6(HDAC6)抑制活性的新型化合物、其立体异构体或其药学上可接受的盐，其在制备治疗药物中的用途，含有其的药物组合物，使用该组合物治疗疾病的方法，以及制备该新型化合物的方法。根据本发明的新型化合物立体异构体或其药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，可有效预防或治疗HDAC6介导的疾病，包括感染性疾病、肿瘤、内分泌、营养和代谢性疾病；精神和行为障碍；神经系统疾病；眼睛和附件疾病；心血管疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；或先天性畸形、变形和染色体异常。
• Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles
  作者：Xiao-Wu Dong、Jian-Kang Zhang、Lei Xu、Jin-Xin Che、Gang Cheng、Xiao-Bei Hu、Li Sheng、An-Hui Gao、Jia Li、Tao Liu、Yong-Zhou Hu、Yu-Bo Zhou

  DOI：10.1016/j.ejmech.2018.12.064

  日期：2019.2

  The potential of specific proteasome inhibitors to act as anti-cancer agents has attracted intensive investigations. The proteasome can be covalently inhibited by epoxyketone derivatives via a two-step reaction. Several computational approaches have been developed to mimic the covalent binding event. Compound 1 composed of a six-membered heterocyclic ring was designed by using covalent docking. With a possible different binding mode from the clinical compound Carfilzomib, it occupied the 55 pocket of 20S proteasome and showed favorable inhibitory activity. Subsequently optimization and evaluation were taken place. Among these compounds, 11h demonstrated extraordinary in vitro inhibitory activity and selectivity, and good in vivo proteasome inhibitory activity, a favorable pharmacokinetic profile and xenograft tumor inhibition. The possible binding pattern of compound 11h against proteasome was further fully explored via calculations, providing a theoretical basis for finding potent proteasome inhibitors. (C) 2018 Elsevier Masson SAS. All rights reserved.
• WO2017/23133
  申请人：——

  公开号：——

  公开（公告）日：——
• The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity
  作者：John G. Cumming、Justin F. Bower、David Waterson、Alan Faull、Philip J. Poyser、Paul Turner、Benjamin McDermott、Andrew D. Campbell、Julian Hudson、Michael James、Jon Winter、Christine Wood

  DOI：10.1016/j.bmcl.2012.04.118

  日期：2012.6

  A novel N-aryl piperazine-1-carboxamide series of human CCR2 chemokine receptor antagonists was discovered. Early analogues were potent at CCR2 but also inhibited the hERG cardiac ion channel. Structural modifications which decreased lipophilicity and basicity resulted in the identification of a sub-series with an improved margin over hERG. The pharmacological and pharmacokinetic properties of the lead compound from this series, N-(3,4-dichlorophenyl)-4-[(2R)-4-isopropylpiperazine-2-carbonyl]piperazine-1-carboxamide, are described. (C) 2012 Elsevier Ltd. All rights reserved.